Management of acquired haemophilia A

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1 S, 2011, Pages 226-235

  Collins, P W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acquired haemophilia; Bypassing agents; Factor VIII; Immunosuppression; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DESMOPRESSIN; HEMOSTATIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; STEROID; VINCRISTINE;

ACQUIRED HEMOPHILIA A; ARTERY THROMBOSIS; BLEEDING; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; ERADICATION THERAPY; HEART INFARCTION; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; SURGICAL TECHNIQUE; VEIN THROMBOSIS;

EID: 79960638859     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04309.x     Document Type: Review

References (95)

1. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
2. Hay CR. Acquired haemophilia. Baillieres Clin Haematol 1998; 11: 287-303.
3. Kessler C, Asatiani E. Acquired inhibitors to factor VIII. In: Lee CA, Berntorp E, Hoots WK, eds. Textbook of Hemophilia. Maassachusetts: Blackwells, 2006: 86-90.
4. Morrison AE, Ludlam CA. Acquired haemophilia and its management. Br J Haematol 1995; 89: 231-6.
5. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-3.
6. Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler C, Levesque H, Castellano M, Shima M, St Louis J. International recommendations on the diagnosis and treatment of patients with acquired haemophilia A. Haematologica 2009; 94: 566-75.
7. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CRM. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7.
8. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250-5.
9. Marco P, Collins P, Knoebl P, Baudo F, Nemes L, Tengborg L, huth-Kuhne A, Pelligrini F. Acquired Haemophilia: clinical and demographic data. Results of European Acquired Haemophilia Registry (EACH2). Blood 2010; 116: Abstract 1398.
10. Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
11. Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pelligrini F, Tengborg L, Huth-Kuhne A. Inhibitor eradication in acquired haemophilia A: final results of European Acquired Haemophilia Registry (EACH2). Blood 2010; 116: Abstract 715.
12. Knoebl P, Collins P, Huth-Kuhne A, Levesque H, Nemes L, Marco P, Tengborg L, Baudo F. Management of bleeding in acquired hemophilia: results of the European Acquired Hemophilia Registry (EACH2). Blood 2010; 116: Abstract 716.
13. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypassing activity (FEIBA): 10 year compilation of thrombotic adverse events. Haemophilia 2001; 8: 83-90.
14. Levesque H, Tengborg L, Marco P, Baudo F, Collins P, Knobl P, Huth-Kuhne A, Nemes L. Acquired haemophilia: descriptive data of the European acquired haemophilia registry (EACH2) J Thromb Haemost 2009; 7: Abstract 116.
15. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
16. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
17. Vadikolia CM, Riddell A, Brooks S, Yee TT, Brown S, Lee C. Acquired haemophilia masked by warfarin therapy. Int J Lab Hematol 2007; 29: 64-8.
18. Dragani A, Febo F, Pennese E, Rolandi G, Spadano A, Davi G. Acquired haemophilia masked by heparin therapy. Int J Immunopathol Pharmacol 2004; 17: 227-8.
19. Uggla B, Linder O, Schulman S. Acquired hemophilia masked by warfarin therapy: report on two cases. Blood Coagul Fibrinolysis 2003; 14: 769-72.
20. Haj M, Dasani H, Kundu S, Mohite U, Collins PW. Acquired haemophilia A may be associated with clopidogrel. BMJ 2004; 329: 323.
21. Hay CRM, Brown SA, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
22. Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF. Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibrinolysis 1998; 9: 623-8.
23. Sahud MA, Pratt KP, Zhukov O, Qu K, Thompson AR. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007; 13: 317-22.
24. Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, Jouan-Flahault C, Horellou MH, Leynadier F, Liozon E, Pouchot J, Robin JP, Sanderson F, Schaeffer A, Sicard D, Staikowsky F, Wechsler B, Zittoun R. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 400-8.
25. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73: 1-5.
26. Italian Association of Haemophilia Centres (AICE). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Registry relevant to clinical practice. BJOG 2006; 110: 311-4.
27. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91: 1067-74.
28. Michiels JJ, Hamulyak K, Nieuwenhuis HK, Novakova I, van Vliet HH. Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur J Haematol 1997; 59: 105-9.
29. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol 1998; 59: 1-4.
30. Nemes L, Tengborg L, Collins P, Baudo F, Huth-Kuhne A, Knoebl P, Marco P, Levesque H. Acquired haemophilia A and pregnancy/postpartum - a report from a European registry. Blood 2010;116: Abstract 717.
31. Dedeken L, St Louis J, Demers C, Meilleur C, Rivard GE. Postpartum acquired haemophilia: a single centre experience with rituximab. Haemophilia 2009; 15: 1166-8.
32. Coller BS, Hultin MB, Hoyer LW, Miller F, Dobbs JV, Dosik MH, Berger ER. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood 1981; 58: 619-24.
33. Ries M, Wolfel D, Maier-Brandt B. Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VIII inhibitor. J Pediatr 1995; 127: 649-50.
34. Lulla RR, Allen GA, Zakarija A, Green D. Transplacental transfer of postpartum inhibitors to factor VIII. Haemophilia 2010; 16: 14-7.
35. Moraca RJ, Ragni MV. Acquired anti-FVIII inhibitors in children. Haemophilia 2002; 8: 28-32.
36. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
37. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-7.
38. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
39. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 2004; 10 (Suppl. 2): 41-5.
40. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13: 451-61.
41. Knoebl P, Collins P, Huth-Kuhne A, Levesque H, Nemes L, Marco P, Tengborg L, Baudo F. Management of bleeding in acquired hemophilia: results of the European Acquired Hemophilia Registry (EACH2). Blood 2010;116: Abstract 716.
42. Aledort LM. Comparitive thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
43. Aledort LM. Comparitive thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitor bypass activity - reply to a rebuttal. J Thromb Haemost 2005; 3: 822.
44. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
45. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
46. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16-22.
47. Varadi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP, Turecek PL. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 11: 2374-80.
48. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
49. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl. 1): 1-6.
50. Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia 2008; 14: 736-42.
51. Freedman J, Rand ML, Russell O, Davis C, Cheatley PL, Blanchette V, Garvey MB. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: 1508-13.
52. Guillet B, Kriaa F, Huysse MG, Proulle V, George C, Tchernia G, D'Oiron R, Laurian Y, Charpentier B, Lambert T, Dreyfus M. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol 2001; 114: 837-44.
53. Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711-6.
54. Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, Vetter H, Brackmann HH. Treatment of acquired hemophilia by the Bonn-Malmo protocol: documentation of an in vivo immunomodulating concept. Blood 2006; 105: 2287-93.
55. Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM, Kasper CK. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.
56. O'Gorman P, Dimichele DM, Kasper CK, Mannucci PM, Santagostini E, Hay CR. Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience. Haemophilia 2001; 7: 537-43.
57. Mahlangu J, Andreeva AT, Macfarland D, Reding MT, Walsh C, Ritchie B, Ewing N, Kessler C, Kempton C, Libby E, Zozulya N, Shapiro AD, St Louis J, Warrier I, Hoots WK, Gruppo R, Mueksch J. A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII. Blood 2007; 110: Abstract 783.
58. Mudad R, Kane WH. DDAVP in acquired hemophilia A: case report and review of the literature. Am J Hematol 1993; 43: 295-9.
59. Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, Wiestner A, Schechter GP. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2006; 11: 13-9.
60. Au WY, Lam CC, Kwong YL. Successful treatment of acquired factor VIII inhibitor with cyclosporin. Haemophilia 2004; 10: 98-100.
61. Bayer RL, Lichtman SM, Allen SL, Budman DR, Buchbinder A, Fetten J, Kolitz J, Loscalzo J. Acquired factor VIII inhibitors - successful treatment with an oral outpatient regimen. Am J Hematol 1999; 60: 70-1.
62. Burnet SP, Duncan EM, Lloyd JV, Han P. Acquired haemophilia in South Australia: a case series. Intern Med J 2001; 31: 556-9.
63. Di Bona E, Schiavoni M, Castaman G, Ciavarella N, Rodeghiero F. Acquired haemophilia: experience of two Italian centres with 17 new cases. Haemophilia 2006; 3: 183-8.
64. Dykes AC, Walker ID, Lowe GD, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 2001; 7: 160-3.
65. Godreuil S, Navarro R, Quittet P, Landreau L, Schved JF, Biron-Andreani C. Acquired haemophilia in the elderly is a severe disease: report of five new cases. Haemophilia 2001; 7: 428-32.
66. Green D. Oral immunosuppressive therapy for acquired hemophilia. Ann Intern Med 1998; 128: 325.
67. Grunewald M, Beneke H, Guthner C, Germowitz A, Brommer A, Griesshammer M. Acquired haemophilia: experiences with a standardized approach. Haemophilia 2001; 7: 164-9.
68. Hart HC, Kraaijenhagen RJ, Kerckhaert JA, Verdel G, Freen M, van de Weil A. A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine. Transpl Proc 1988; 20 (Suppl. 4): 323-8.
69. Huang YW, Saidi P, Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Haemophilia 2004; 10: 713-21.
70. Hultin MB, Shapiro SS, Bowman HS, Gill FM, Andrews AT, Martinez J, Eyster EM, Sherwood WC. Immunosuppressive therapy of Factor VIII inhibitors. Blood 1976; 48: 95-108.
71. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).[comment]. Br J Haematol 2002; 119: 578.
72. Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-8.
73. Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol 2002; 69: 294-5.
74. Pardos-Gea J, Ordi-Ros J, Altisent C, Balada E, Perez-Lopez J, Vilardell M. Acquired haemophilia A: successful treatment with immunosuppression, methylprednisolone pulses and oral cyclosporin. Thromb Haemost 2006; 95: 735-7.
75. Sallah S, Singh P, Hanrahan LR. Antibodies against factor VIII in patients with solid tumors: successful treatment of cancer may suppress inhibitor formation. Haemostasis 1998; 28: 244-9.
76. Saxena R, Mishra DK, Kashyap R, Choudhry VP, Mahapatra M, Bhargava M. Acquired haemophilia - a study of ten cases. Haemophilia 2000; 6: 78-83.
77. Schulman S, Langevitz P, Livneh A, Mortinowitz U, Seligsohn U, Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76: 344-6.
78. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797-804.
79. Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997; 127: 206-9.
80. Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 1981; 48: 635-42.
81. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
82. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
83. Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol 2000; 22: 275-8.
84. Ng HJ, Tan DC, Lee LH. Treatment and outcome of acquired haemophilia A with a standard conventional regimen in a cohort without associated conditions. Haemophilia 2006; 12: 423-8.
85. Sohngen D, Specker C, Bach D, Kuntz BM, Burk M, Aul C, Kobbe G, Heyll A, Hollmig KA, Schneider W. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol 1997; 74: 89-93.
86. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-5.
87. Lak M, Sharifian RA, Karimi K, Mansouritorghabeh H. Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa. Clin Appl Thromb Hemost 2010; 16: 294-300.
88. Collins PW, Baudo F, Huth-Kuhne A, Knobl P, Levesque H, Marco P, Nemes L, Peerlinck K, Tengborg L. Firstline immunosuppressive treatment for acquired factor VIII antibodies: results of the European acquired haemophilia registry (EACH2). J Thromb Haemost 2009;7 (Suppl. 2):526: Abstract 609.
89. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
90. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141: 149-69.
91. Adedayo AA, Skorupa A, Lal A, Ronsih E, Mercier RJ, Islam R. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 87.
92. Pfliegler G, Boda Z, Harsfalvi J, Flora-Nagy M, Sari B, Pecze K, Rak K. Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor. Postgrad Med J 1989; 65: 400-2.
93. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85 (10 Suppl.): 64-8.
94. Ji L, Yang R, Yang D, Chen Z, Xing S, Tian M, Sun Y. Prednislone and low-dose activated prothrombin complex concentrates for FVIII inhibitor in nonhemophilic patients. Haemophilia 2006; 4: 721-4.
95. Mazzucconi MG, Bizzoni L, Giorgi A, Morano SG, Peraino M, Russo M, Alimena G. Postpartum inhibitor to factor VIII: treatment with high-dose immunoglobulin and dexamethasone. Haemophilia 2001; 7: 422-7.